nodes	percent_of_prediction	percent_of_DWPC	metapath
Trihexyphenidyl—Vomiting—Cladribine—hematologic cancer	0.000714	0.000954	CcSEcCtD
Trihexyphenidyl—Dizziness—Vinblastine—hematologic cancer	0.000712	0.000951	CcSEcCtD
Trihexyphenidyl—Rash—Cladribine—hematologic cancer	0.000708	0.000946	CcSEcCtD
Trihexyphenidyl—Hallucination—Betamethasone—hematologic cancer	0.000708	0.000945	CcSEcCtD
Trihexyphenidyl—Hallucination—Dexamethasone—hematologic cancer	0.000708	0.000945	CcSEcCtD
Trihexyphenidyl—Dermatitis—Cladribine—hematologic cancer	0.000707	0.000945	CcSEcCtD
Trihexyphenidyl—Constipation—Thalidomide—hematologic cancer	0.000707	0.000944	CcSEcCtD
Trihexyphenidyl—Somnolence—Carmustine—hematologic cancer	0.000706	0.000943	CcSEcCtD
Trihexyphenidyl—Asthenia—Hydroxyurea—hematologic cancer	0.000705	0.000941	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Thiotepa—hematologic cancer	0.000704	0.000941	CcSEcCtD
Trihexyphenidyl—Headache—Cladribine—hematologic cancer	0.000703	0.00094	CcSEcCtD
Trihexyphenidyl—Weight decreased—Prednisone—hematologic cancer	0.0007	0.000935	CcSEcCtD
Trihexyphenidyl—Vision blurred—Prednisolone—hematologic cancer	0.000699	0.000934	CcSEcCtD
Trihexyphenidyl—Somnolence—Alitretinoin—hematologic cancer	0.000699	0.000934	CcSEcCtD
Trihexyphenidyl—Nausea—Chlorambucil—hematologic cancer	0.000698	0.000932	CcSEcCtD
Trihexyphenidyl—Somnolence—Ifosfamide—hematologic cancer	0.000691	0.000923	CcSEcCtD
Trihexyphenidyl—Vomiting—Vinblastine—hematologic cancer	0.000685	0.000915	CcSEcCtD
Trihexyphenidyl—Nausea—Nilotinib—hematologic cancer	0.000683	0.000912	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Thalidomide—hematologic cancer	0.000681	0.00091	CcSEcCtD
Trihexyphenidyl—Constipation—Carmustine—hematologic cancer	0.000679	0.000907	CcSEcCtD
Trihexyphenidyl—Nausea—Imatinib—hematologic cancer	0.000679	0.000907	CcSEcCtD
Trihexyphenidyl—Headache—Vinblastine—hematologic cancer	0.000675	0.000901	CcSEcCtD
Trihexyphenidyl—Constipation—Alitretinoin—hematologic cancer	0.000672	0.000898	CcSEcCtD
Trihexyphenidyl—Nausea—Cladribine—hematologic cancer	0.000667	0.000891	CcSEcCtD
Trihexyphenidyl—Constipation—Ifosfamide—hematologic cancer	0.000665	0.000888	CcSEcCtD
Trihexyphenidyl—Dizziness—Lenalidomide—hematologic cancer	0.000659	0.00088	CcSEcCtD
Trihexyphenidyl—Asthenia—Bortezomib—hematologic cancer	0.000658	0.000878	CcSEcCtD
Trihexyphenidyl—Somnolence—Irinotecan—hematologic cancer	0.000656	0.000876	CcSEcCtD
Trihexyphenidyl—Somnolence—Mitoxantrone—hematologic cancer	0.000656	0.000876	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Carmustine—hematologic cancer	0.000654	0.000874	CcSEcCtD
Trihexyphenidyl—Tachycardia—Cisplatin—hematologic cancer	0.000654	0.000874	CcSEcCtD
Trihexyphenidyl—Asthenia—Bleomycin—hematologic cancer	0.000652	0.000872	CcSEcCtD
Trihexyphenidyl—Vomiting—Melphalan—hematologic cancer	0.000651	0.00087	CcSEcCtD
Trihexyphenidyl—Dizziness—Hydroxyurea—hematologic cancer	0.000649	0.000867	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Alitretinoin—hematologic cancer	0.000648	0.000866	CcSEcCtD
Trihexyphenidyl—Constipation—Vincristine—hematologic cancer	0.000648	0.000866	CcSEcCtD
Trihexyphenidyl—Rash—Melphalan—hematologic cancer	0.000646	0.000863	CcSEcCtD
Trihexyphenidyl—Dermatitis—Melphalan—hematologic cancer	0.000645	0.000862	CcSEcCtD
Trihexyphenidyl—Asthenia—Vinorelbine—hematologic cancer	0.000642	0.000858	CcSEcCtD
Trihexyphenidyl—Dry skin—Epirubicin—hematologic cancer	0.000642	0.000857	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Ifosfamide—hematologic cancer	0.00064	0.000856	CcSEcCtD
Trihexyphenidyl—Nausea—Vinblastine—hematologic cancer	0.00064	0.000854	CcSEcCtD
Trihexyphenidyl—Somnolence—Gemcitabine—hematologic cancer	0.000639	0.000854	CcSEcCtD
Trihexyphenidyl—Vomiting—Lenalidomide—hematologic cancer	0.000633	0.000846	CcSEcCtD
Trihexyphenidyl—Constipation—Irinotecan—hematologic cancer	0.000631	0.000843	CcSEcCtD
Trihexyphenidyl—Constipation—Mitoxantrone—hematologic cancer	0.000631	0.000843	CcSEcCtD
Trihexyphenidyl—Rash—Lenalidomide—hematologic cancer	0.000628	0.000839	CcSEcCtD
Trihexyphenidyl—Dermatitis—Lenalidomide—hematologic cancer	0.000627	0.000838	CcSEcCtD
Trihexyphenidyl—Vomiting—Hydroxyurea—hematologic cancer	0.000624	0.000834	CcSEcCtD
Trihexyphenidyl—Headache—Lenalidomide—hematologic cancer	0.000624	0.000833	CcSEcCtD
Trihexyphenidyl—Rash—Hydroxyurea—hematologic cancer	0.000619	0.000827	CcSEcCtD
Trihexyphenidyl—Confusional state—Etoposide—hematologic cancer	0.000619	0.000827	CcSEcCtD
Trihexyphenidyl—Dermatitis—Hydroxyurea—hematologic cancer	0.000619	0.000826	CcSEcCtD
Trihexyphenidyl—Hallucination—Prednisone—hematologic cancer	0.000616	0.000823	CcSEcCtD
Trihexyphenidyl—Headache—Hydroxyurea—hematologic cancer	0.000615	0.000822	CcSEcCtD
Trihexyphenidyl—Constipation—Gemcitabine—hematologic cancer	0.000615	0.000821	CcSEcCtD
Trihexyphenidyl—Asthenia—Thiotepa—hematologic cancer	0.000613	0.000819	CcSEcCtD
Trihexyphenidyl—Nausea—Melphalan—hematologic cancer	0.000608	0.000813	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Irinotecan—hematologic cancer	0.000608	0.000812	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Mitoxantrone—hematologic cancer	0.000608	0.000812	CcSEcCtD
Trihexyphenidyl—Dizziness—Bortezomib—hematologic cancer	0.000606	0.00081	CcSEcCtD
Trihexyphenidyl—Tachycardia—Etoposide—hematologic cancer	0.000599	0.0008	CcSEcCtD
Trihexyphenidyl—Dry skin—Doxorubicin—hematologic cancer	0.000594	0.000793	CcSEcCtD
Trihexyphenidyl—Asthenia—Thalidomide—hematologic cancer	0.000593	0.000792	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Gemcitabine—hematologic cancer	0.000592	0.000791	CcSEcCtD
Trihexyphenidyl—Dizziness—Vinorelbine—hematologic cancer	0.000592	0.00079	CcSEcCtD
Trihexyphenidyl—Nausea—Lenalidomide—hematologic cancer	0.000592	0.00079	CcSEcCtD
Trihexyphenidyl—Tachycardia—Prednisolone—hematologic cancer	0.000591	0.000789	CcSEcCtD
Trihexyphenidyl—Nausea—Hydroxyurea—hematologic cancer	0.000583	0.000779	CcSEcCtD
Trihexyphenidyl—Vomiting—Bortezomib—hematologic cancer	0.000583	0.000778	CcSEcCtD
Trihexyphenidyl—Vomiting—Bleomycin—hematologic cancer	0.000578	0.000772	CcSEcCtD
Trihexyphenidyl—Rash—Bortezomib—hematologic cancer	0.000578	0.000772	CcSEcCtD
Trihexyphenidyl—Dermatitis—Bortezomib—hematologic cancer	0.000577	0.000771	CcSEcCtD
Trihexyphenidyl—Drowsiness—Methotrexate—hematologic cancer	0.000577	0.00077	CcSEcCtD
Trihexyphenidyl—Headache—Bortezomib—hematologic cancer	0.000574	0.000767	CcSEcCtD
Trihexyphenidyl—Rash—Bleomycin—hematologic cancer	0.000573	0.000766	CcSEcCtD
Trihexyphenidyl—Dermatitis—Bleomycin—hematologic cancer	0.000573	0.000765	CcSEcCtD
Trihexyphenidyl—Asthenia—Carmustine—hematologic cancer	0.00057	0.000761	CcSEcCtD
Trihexyphenidyl—Vomiting—Vinorelbine—hematologic cancer	0.000569	0.00076	CcSEcCtD
Trihexyphenidyl—Dizziness—Thiotepa—hematologic cancer	0.000565	0.000755	CcSEcCtD
Trihexyphenidyl—Asthenia—Alitretinoin—hematologic cancer	0.000564	0.000754	CcSEcCtD
Trihexyphenidyl—Rash—Vinorelbine—hematologic cancer	0.000564	0.000754	CcSEcCtD
Trihexyphenidyl—Dermatitis—Vinorelbine—hematologic cancer	0.000564	0.000753	CcSEcCtD
Trihexyphenidyl—Headache—Vinorelbine—hematologic cancer	0.000561	0.000749	CcSEcCtD
Trihexyphenidyl—Asthenia—Ifosfamide—hematologic cancer	0.000558	0.000745	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Cisplatin—hematologic cancer	0.000552	0.000738	CcSEcCtD
Trihexyphenidyl—Weight decreased—Epirubicin—hematologic cancer	0.000547	0.000731	CcSEcCtD
Trihexyphenidyl—Dizziness—Thalidomide—hematologic cancer	0.000547	0.00073	CcSEcCtD
Trihexyphenidyl—Somnolence—Etoposide—hematologic cancer	0.000546	0.000729	CcSEcCtD
Trihexyphenidyl—Nausea—Bortezomib—hematologic cancer	0.000544	0.000727	CcSEcCtD
Trihexyphenidyl—Asthenia—Vincristine—hematologic cancer	0.000544	0.000726	CcSEcCtD
Trihexyphenidyl—Tachycardia—Triamcinolone—hematologic cancer	0.000543	0.000726	CcSEcCtD
Trihexyphenidyl—Vomiting—Thiotepa—hematologic cancer	0.000543	0.000726	CcSEcCtD
Trihexyphenidyl—Nausea—Bleomycin—hematologic cancer	0.00054	0.000722	CcSEcCtD
Trihexyphenidyl—Drowsiness—Epirubicin—hematologic cancer	0.00054	0.000721	CcSEcCtD
Trihexyphenidyl—Rash—Thiotepa—hematologic cancer	0.000539	0.00072	CcSEcCtD
Trihexyphenidyl—Dermatitis—Thiotepa—hematologic cancer	0.000538	0.000719	CcSEcCtD
Trihexyphenidyl—Headache—Thiotepa—hematologic cancer	0.000535	0.000715	CcSEcCtD
Trihexyphenidyl—Nausea—Vinorelbine—hematologic cancer	0.000532	0.00071	CcSEcCtD
Trihexyphenidyl—Asthenia—Mitoxantrone—hematologic cancer	0.000529	0.000707	CcSEcCtD
Trihexyphenidyl—Asthenia—Irinotecan—hematologic cancer	0.000529	0.000707	CcSEcCtD
Trihexyphenidyl—Vomiting—Thalidomide—hematologic cancer	0.000526	0.000702	CcSEcCtD
Trihexyphenidyl—Dizziness—Carmustine—hematologic cancer	0.000525	0.000701	CcSEcCtD
Trihexyphenidyl—Constipation—Etoposide—hematologic cancer	0.000525	0.000701	CcSEcCtD
Trihexyphenidyl—Rash—Thalidomide—hematologic cancer	0.000521	0.000696	CcSEcCtD
Trihexyphenidyl—Dermatitis—Thalidomide—hematologic cancer	0.000521	0.000696	CcSEcCtD
Trihexyphenidyl—Dizziness—Alitretinoin—hematologic cancer	0.00052	0.000695	CcSEcCtD
Trihexyphenidyl—Headache—Thalidomide—hematologic cancer	0.000518	0.000692	CcSEcCtD
Trihexyphenidyl—Asthenia—Gemcitabine—hematologic cancer	0.000516	0.000689	CcSEcCtD
Trihexyphenidyl—Dizziness—Ifosfamide—hematologic cancer	0.000514	0.000687	CcSEcCtD
Trihexyphenidyl—Vision blurred—Prednisone—hematologic cancer	0.000508	0.000679	CcSEcCtD
Trihexyphenidyl—Nausea—Thiotepa—hematologic cancer	0.000508	0.000678	CcSEcCtD
Trihexyphenidyl—Weight decreased—Doxorubicin—hematologic cancer	0.000507	0.000677	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Etoposide—hematologic cancer	0.000506	0.000676	CcSEcCtD
Trihexyphenidyl—Vomiting—Carmustine—hematologic cancer	0.000505	0.000674	CcSEcCtD
Trihexyphenidyl—Dizziness—Vincristine—hematologic cancer	0.000501	0.000669	CcSEcCtD
Trihexyphenidyl—Rash—Carmustine—hematologic cancer	0.000501	0.000669	CcSEcCtD
Trihexyphenidyl—Dermatitis—Carmustine—hematologic cancer	0.0005	0.000668	CcSEcCtD
Trihexyphenidyl—Vomiting—Alitretinoin—hematologic cancer	0.0005	0.000668	CcSEcCtD
Trihexyphenidyl—Drowsiness—Doxorubicin—hematologic cancer	0.000499	0.000667	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Prednisolone—hematologic cancer	0.000499	0.000667	CcSEcCtD
Trihexyphenidyl—Headache—Carmustine—hematologic cancer	0.000497	0.000664	CcSEcCtD
Trihexyphenidyl—Rash—Alitretinoin—hematologic cancer	0.000496	0.000662	CcSEcCtD
Trihexyphenidyl—Agitation—Prednisone—hematologic cancer	0.000495	0.000662	CcSEcCtD
Trihexyphenidyl—Dermatitis—Alitretinoin—hematologic cancer	0.000495	0.000662	CcSEcCtD
Trihexyphenidyl—Vomiting—Ifosfamide—hematologic cancer	0.000494	0.00066	CcSEcCtD
Trihexyphenidyl—Tachycardia—Dexamethasone—hematologic cancer	0.000493	0.000659	CcSEcCtD
Trihexyphenidyl—Tachycardia—Betamethasone—hematologic cancer	0.000493	0.000659	CcSEcCtD
Trihexyphenidyl—Headache—Alitretinoin—hematologic cancer	0.000493	0.000658	CcSEcCtD
Trihexyphenidyl—Nausea—Thalidomide—hematologic cancer	0.000491	0.000656	CcSEcCtD
Trihexyphenidyl—Rash—Ifosfamide—hematologic cancer	0.00049	0.000655	CcSEcCtD
Trihexyphenidyl—Dermatitis—Ifosfamide—hematologic cancer	0.00049	0.000654	CcSEcCtD
Trihexyphenidyl—Dizziness—Irinotecan—hematologic cancer	0.000488	0.000652	CcSEcCtD
Trihexyphenidyl—Vomiting—Vincristine—hematologic cancer	0.000482	0.000644	CcSEcCtD
Trihexyphenidyl—Asthenia—Cisplatin—hematologic cancer	0.000481	0.000642	CcSEcCtD
Trihexyphenidyl—Rash—Vincristine—hematologic cancer	0.000478	0.000638	CcSEcCtD
Trihexyphenidyl—Dermatitis—Vincristine—hematologic cancer	0.000477	0.000638	CcSEcCtD
Trihexyphenidyl—Headache—Vincristine—hematologic cancer	0.000475	0.000634	CcSEcCtD
Trihexyphenidyl—Nausea—Carmustine—hematologic cancer	0.000472	0.00063	CcSEcCtD
Trihexyphenidyl—Vomiting—Mitoxantrone—hematologic cancer	0.000469	0.000627	CcSEcCtD
Trihexyphenidyl—Vomiting—Irinotecan—hematologic cancer	0.000469	0.000627	CcSEcCtD
Trihexyphenidyl—Nausea—Alitretinoin—hematologic cancer	0.000467	0.000624	CcSEcCtD
Trihexyphenidyl—Rash—Mitoxantrone—hematologic cancer	0.000465	0.000622	CcSEcCtD
Trihexyphenidyl—Rash—Irinotecan—hematologic cancer	0.000465	0.000622	CcSEcCtD
Trihexyphenidyl—Dermatitis—Mitoxantrone—hematologic cancer	0.000465	0.000621	CcSEcCtD
Trihexyphenidyl—Dermatitis—Irinotecan—hematologic cancer	0.000465	0.000621	CcSEcCtD
Trihexyphenidyl—Headache—Mitoxantrone—hematologic cancer	0.000462	0.000618	CcSEcCtD
Trihexyphenidyl—Headache—Irinotecan—hematologic cancer	0.000462	0.000618	CcSEcCtD
Trihexyphenidyl—Nausea—Ifosfamide—hematologic cancer	0.000462	0.000617	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Triamcinolone—hematologic cancer	0.000459	0.000613	CcSEcCtD
Trihexyphenidyl—Vomiting—Gemcitabine—hematologic cancer	0.000457	0.000611	CcSEcCtD
Trihexyphenidyl—Rash—Gemcitabine—hematologic cancer	0.000453	0.000606	CcSEcCtD
Trihexyphenidyl—Dermatitis—Gemcitabine—hematologic cancer	0.000453	0.000605	CcSEcCtD
Trihexyphenidyl—Headache—Gemcitabine—hematologic cancer	0.00045	0.000602	CcSEcCtD
Trihexyphenidyl—Nausea—Vincristine—hematologic cancer	0.00045	0.000601	CcSEcCtD
Trihexyphenidyl—Asthenia—Etoposide—hematologic cancer	0.00044	0.000588	CcSEcCtD
Trihexyphenidyl—Nausea—Mitoxantrone—hematologic cancer	0.000438	0.000586	CcSEcCtD
Trihexyphenidyl—Nausea—Irinotecan—hematologic cancer	0.000438	0.000586	CcSEcCtD
Trihexyphenidyl—Tachycardia—Prednisone—hematologic cancer	0.000429	0.000574	CcSEcCtD
Trihexyphenidyl—Nausea—Gemcitabine—hematologic cancer	0.000427	0.00057	CcSEcCtD
Trihexyphenidyl—Vomiting—Cisplatin—hematologic cancer	0.000426	0.000569	CcSEcCtD
Trihexyphenidyl—Vision blurred—Methotrexate—hematologic cancer	0.000425	0.000567	CcSEcCtD
Trihexyphenidyl—Rash—Cisplatin—hematologic cancer	0.000422	0.000564	CcSEcCtD
Trihexyphenidyl—Dermatitis—Cisplatin—hematologic cancer	0.000422	0.000564	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Dexamethasone—hematologic cancer	0.000416	0.000556	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Betamethasone—hematologic cancer	0.000416	0.000556	CcSEcCtD
Trihexyphenidyl—Tension—Epirubicin—hematologic cancer	0.000414	0.000553	CcSEcCtD
Trihexyphenidyl—Nervousness—Epirubicin—hematologic cancer	0.000409	0.000547	CcSEcCtD
Trihexyphenidyl—Dizziness—Etoposide—hematologic cancer	0.000406	0.000542	CcSEcCtD
Trihexyphenidyl—Dizziness—Prednisolone—hematologic cancer	0.0004	0.000535	CcSEcCtD
Trihexyphenidyl—Asthenia—Triamcinolone—hematologic cancer	0.000399	0.000534	CcSEcCtD
Trihexyphenidyl—Nausea—Cisplatin—hematologic cancer	0.000398	0.000532	CcSEcCtD
Trihexyphenidyl—Vision blurred—Epirubicin—hematologic cancer	0.000397	0.000531	CcSEcCtD
Trihexyphenidyl—Vomiting—Etoposide—hematologic cancer	0.00039	0.000521	CcSEcCtD
Trihexyphenidyl—Agitation—Epirubicin—hematologic cancer	0.000387	0.000518	CcSEcCtD
Trihexyphenidyl—Rash—Etoposide—hematologic cancer	0.000387	0.000517	CcSEcCtD
Trihexyphenidyl—Dermatitis—Etoposide—hematologic cancer	0.000387	0.000517	CcSEcCtD
Trihexyphenidyl—Headache—Etoposide—hematologic cancer	0.000385	0.000514	CcSEcCtD
Trihexyphenidyl—Tension—Doxorubicin—hematologic cancer	0.000383	0.000511	CcSEcCtD
Trihexyphenidyl—Rash—Prednisolone—hematologic cancer	0.000382	0.00051	CcSEcCtD
Trihexyphenidyl—Dermatitis—Prednisolone—hematologic cancer	0.000381	0.00051	CcSEcCtD
Trihexyphenidyl—Headache—Prednisolone—hematologic cancer	0.000379	0.000507	CcSEcCtD
Trihexyphenidyl—Nervousness—Doxorubicin—hematologic cancer	0.000379	0.000506	CcSEcCtD
Trihexyphenidyl—Constipation—Prednisone—hematologic cancer	0.000376	0.000503	CcSEcCtD
Trihexyphenidyl—Confusional state—Methotrexate—hematologic cancer	0.000371	0.000495	CcSEcCtD
Trihexyphenidyl—Dizziness—Triamcinolone—hematologic cancer	0.000368	0.000492	CcSEcCtD
Trihexyphenidyl—Vision blurred—Doxorubicin—hematologic cancer	0.000368	0.000491	CcSEcCtD
Trihexyphenidyl—Nausea—Etoposide—hematologic cancer	0.000365	0.000487	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Prednisone—hematologic cancer	0.000363	0.000484	CcSEcCtD
Trihexyphenidyl—Asthenia—Dexamethasone—hematologic cancer	0.000362	0.000484	CcSEcCtD
Trihexyphenidyl—Asthenia—Betamethasone—hematologic cancer	0.000362	0.000484	CcSEcCtD
Trihexyphenidyl—Nausea—Prednisolone—hematologic cancer	0.00036	0.00048	CcSEcCtD
Trihexyphenidyl—Agitation—Doxorubicin—hematologic cancer	0.000358	0.000479	CcSEcCtD
Trihexyphenidyl—Vomiting—Triamcinolone—hematologic cancer	0.000354	0.000473	CcSEcCtD
Trihexyphenidyl—Rash—Triamcinolone—hematologic cancer	0.000351	0.000469	CcSEcCtD
Trihexyphenidyl—Dermatitis—Triamcinolone—hematologic cancer	0.000351	0.000469	CcSEcCtD
Trihexyphenidyl—Headache—Triamcinolone—hematologic cancer	0.000349	0.000466	CcSEcCtD
Trihexyphenidyl—Confusional state—Epirubicin—hematologic cancer	0.000347	0.000464	CcSEcCtD
Trihexyphenidyl—Tachycardia—Epirubicin—hematologic cancer	0.000336	0.000449	CcSEcCtD
Trihexyphenidyl—Dizziness—Betamethasone—hematologic cancer	0.000334	0.000446	CcSEcCtD
Trihexyphenidyl—Dizziness—Dexamethasone—hematologic cancer	0.000334	0.000446	CcSEcCtD
Trihexyphenidyl—Nausea—Triamcinolone—hematologic cancer	0.000331	0.000442	CcSEcCtD
Trihexyphenidyl—Somnolence—Methotrexate—hematologic cancer	0.000327	0.000437	CcSEcCtD
Trihexyphenidyl—Vomiting—Dexamethasone—hematologic cancer	0.000321	0.000429	CcSEcCtD
Trihexyphenidyl—Vomiting—Betamethasone—hematologic cancer	0.000321	0.000429	CcSEcCtD
Trihexyphenidyl—Confusional state—Doxorubicin—hematologic cancer	0.000321	0.000429	CcSEcCtD
Trihexyphenidyl—Rash—Betamethasone—hematologic cancer	0.000319	0.000426	CcSEcCtD
Trihexyphenidyl—Rash—Dexamethasone—hematologic cancer	0.000319	0.000426	CcSEcCtD
Trihexyphenidyl—Dermatitis—Dexamethasone—hematologic cancer	0.000318	0.000425	CcSEcCtD
Trihexyphenidyl—Dermatitis—Betamethasone—hematologic cancer	0.000318	0.000425	CcSEcCtD
Trihexyphenidyl—Headache—Dexamethasone—hematologic cancer	0.000316	0.000423	CcSEcCtD
Trihexyphenidyl—Headache—Betamethasone—hematologic cancer	0.000316	0.000423	CcSEcCtD
Trihexyphenidyl—Asthenia—Prednisone—hematologic cancer	0.000316	0.000422	CcSEcCtD
Trihexyphenidyl—Tachycardia—Doxorubicin—hematologic cancer	0.000311	0.000415	CcSEcCtD
Trihexyphenidyl—Somnolence—Epirubicin—hematologic cancer	0.000306	0.000409	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Methotrexate—hematologic cancer	0.000303	0.000405	CcSEcCtD
Trihexyphenidyl—Nausea—Dexamethasone—hematologic cancer	0.0003	0.000401	CcSEcCtD
Trihexyphenidyl—Nausea—Betamethasone—hematologic cancer	0.0003	0.000401	CcSEcCtD
Trihexyphenidyl—Constipation—Epirubicin—hematologic cancer	0.000294	0.000393	CcSEcCtD
Trihexyphenidyl—Dizziness—Prednisone—hematologic cancer	0.000291	0.000389	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Epirubicin—hematologic cancer	0.000284	0.000379	CcSEcCtD
Trihexyphenidyl—Somnolence—Doxorubicin—hematologic cancer	0.000283	0.000378	CcSEcCtD
Trihexyphenidyl—Vomiting—Prednisone—hematologic cancer	0.00028	0.000374	CcSEcCtD
Trihexyphenidyl—Rash—Prednisone—hematologic cancer	0.000277	0.000371	CcSEcCtD
Trihexyphenidyl—Dermatitis—Prednisone—hematologic cancer	0.000277	0.00037	CcSEcCtD
Trihexyphenidyl—Headache—Prednisone—hematologic cancer	0.000276	0.000368	CcSEcCtD
Trihexyphenidyl—Constipation—Doxorubicin—hematologic cancer	0.000272	0.000364	CcSEcCtD
Trihexyphenidyl—Asthenia—Methotrexate—hematologic cancer	0.000264	0.000352	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Doxorubicin—hematologic cancer	0.000262	0.00035	CcSEcCtD
Trihexyphenidyl—Nausea—Prednisone—hematologic cancer	0.000261	0.000349	CcSEcCtD
Trihexyphenidyl—Asthenia—Epirubicin—hematologic cancer	0.000247	0.00033	CcSEcCtD
Trihexyphenidyl—Dizziness—Methotrexate—hematologic cancer	0.000243	0.000325	CcSEcCtD
Trihexyphenidyl—Vomiting—Methotrexate—hematologic cancer	0.000234	0.000312	CcSEcCtD
Trihexyphenidyl—Rash—Methotrexate—hematologic cancer	0.000232	0.00031	CcSEcCtD
Trihexyphenidyl—Dermatitis—Methotrexate—hematologic cancer	0.000232	0.000309	CcSEcCtD
Trihexyphenidyl—Headache—Methotrexate—hematologic cancer	0.00023	0.000308	CcSEcCtD
Trihexyphenidyl—Asthenia—Doxorubicin—hematologic cancer	0.000228	0.000305	CcSEcCtD
Trihexyphenidyl—Dizziness—Epirubicin—hematologic cancer	0.000228	0.000304	CcSEcCtD
Trihexyphenidyl—Vomiting—Epirubicin—hematologic cancer	0.000219	0.000292	CcSEcCtD
Trihexyphenidyl—Nausea—Methotrexate—hematologic cancer	0.000218	0.000292	CcSEcCtD
Trihexyphenidyl—Rash—Epirubicin—hematologic cancer	0.000217	0.00029	CcSEcCtD
Trihexyphenidyl—Dermatitis—Epirubicin—hematologic cancer	0.000217	0.00029	CcSEcCtD
Trihexyphenidyl—Headache—Epirubicin—hematologic cancer	0.000216	0.000288	CcSEcCtD
Trihexyphenidyl—Dizziness—Doxorubicin—hematologic cancer	0.000211	0.000281	CcSEcCtD
Trihexyphenidyl—Nausea—Epirubicin—hematologic cancer	0.000204	0.000273	CcSEcCtD
Trihexyphenidyl—Vomiting—Doxorubicin—hematologic cancer	0.000202	0.00027	CcSEcCtD
Trihexyphenidyl—Rash—Doxorubicin—hematologic cancer	0.000201	0.000268	CcSEcCtD
Trihexyphenidyl—Dermatitis—Doxorubicin—hematologic cancer	0.000201	0.000268	CcSEcCtD
Trihexyphenidyl—Headache—Doxorubicin—hematologic cancer	0.000199	0.000266	CcSEcCtD
Trihexyphenidyl—Nausea—Doxorubicin—hematologic cancer	0.000189	0.000253	CcSEcCtD
Trihexyphenidyl—CHRM3—Metabolism—PIK3CG—hematologic cancer	2.84e-05	0.000113	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—IL2—hematologic cancer	2.84e-05	0.000113	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—IL2—hematologic cancer	2.83e-05	0.000113	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—TERT—hematologic cancer	2.83e-05	0.000113	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—IL2RA—hematologic cancer	2.83e-05	0.000112	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—TERT—hematologic cancer	2.82e-05	0.000112	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—PIK3R1—hematologic cancer	2.81e-05	0.000112	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—IL2—hematologic cancer	2.8e-05	0.000112	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling by GPCR—PIK3CA—hematologic cancer	2.8e-05	0.000111	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—TERT—hematologic cancer	2.79e-05	0.000111	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—MDM2—hematologic cancer	2.79e-05	0.000111	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—PDGFB—hematologic cancer	2.76e-05	0.00011	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—PDGFB—hematologic cancer	2.75e-05	0.00011	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—JAK2—hematologic cancer	2.73e-05	0.000109	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—PDGFB—hematologic cancer	2.73e-05	0.000108	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—MTOR—hematologic cancer	2.71e-05	0.000108	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—PIK3CB—hematologic cancer	2.71e-05	0.000108	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—TSC2—hematologic cancer	2.7e-05	0.000107	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—TSC2—hematologic cancer	2.69e-05	0.000107	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling by GPCR—PIK3CA—hematologic cancer	2.68e-05	0.000107	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—MDM2—hematologic cancer	2.67e-05	0.000106	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—TSC2—hematologic cancer	2.67e-05	0.000106	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—CREBBP—hematologic cancer	2.64e-05	0.000105	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—FGFR3—hematologic cancer	2.6e-05	0.000103	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—MTOR—hematologic cancer	2.6e-05	0.000103	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—PIK3CB—hematologic cancer	2.6e-05	0.000103	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—FGFR3—hematologic cancer	2.59e-05	0.000103	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling by GPCR—HRAS—hematologic cancer	2.59e-05	0.000103	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—MAPK14—hematologic cancer	2.57e-05	0.000102	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—FGFR3—hematologic cancer	2.56e-05	0.000102	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—MAPK14—hematologic cancer	2.56e-05	0.000102	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—CDKN1B—hematologic cancer	2.54e-05	0.000101	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—MAPK14—hematologic cancer	2.54e-05	0.000101	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—ESR1—hematologic cancer	2.52e-05	0.0001	CbGpPWpGaD
Trihexyphenidyl—CHRM4—GPCR downstream signaling—AKT1—hematologic cancer	2.52e-05	0.0001	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—ESR1—hematologic cancer	2.52e-05	0.0001	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—PIK3CD—hematologic cancer	2.5e-05	9.94e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—CASP3—hematologic cancer	2.49e-05	9.91e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—FN1—hematologic cancer	2.49e-05	9.91e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—ESR1—hematologic cancer	2.49e-05	9.9e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—IL2—hematologic cancer	2.49e-05	9.9e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—FN1—hematologic cancer	2.48e-05	9.88e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling by GPCR—HRAS—hematologic cancer	2.48e-05	9.85e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling by GPCR—IL6—hematologic cancer	2.48e-05	9.85e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—ALB—hematologic cancer	2.47e-05	9.81e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—BAD—hematologic cancer	2.46e-05	9.79e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—NFKBIA—hematologic cancer	2.46e-05	9.79e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—FN1—hematologic cancer	2.46e-05	9.78e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—BAD—hematologic cancer	2.45e-05	9.76e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—NFKBIA—hematologic cancer	2.45e-05	9.76e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—NOTCH1—hematologic cancer	2.44e-05	9.7e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—CDKN1B—hematologic cancer	2.44e-05	9.69e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—NOTCH1—hematologic cancer	2.43e-05	9.67e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—BAD—hematologic cancer	2.43e-05	9.67e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—NFKBIA—hematologic cancer	2.43e-05	9.67e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—CCND1—hematologic cancer	2.43e-05	9.65e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—JUN—hematologic cancer	2.42e-05	9.63e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—GPCR downstream signaling—AKT1—hematologic cancer	2.41e-05	9.58e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—NOTCH1—hematologic cancer	2.41e-05	9.57e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—CD80—hematologic cancer	2.39e-05	9.5e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—CASP3—hematologic cancer	2.39e-05	9.49e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—KIT—hematologic cancer	2.38e-05	9.48e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—PIK3CG—hematologic cancer	2.38e-05	9.48e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—NRAS—hematologic cancer	2.38e-05	9.48e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—IL2—hematologic cancer	2.38e-05	9.48e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—CD80—hematologic cancer	2.38e-05	9.47e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—PIK3CG—hematologic cancer	2.38e-05	9.45e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—KIT—hematologic cancer	2.38e-05	9.45e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—NRAS—hematologic cancer	2.38e-05	9.45e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling by GPCR—IL6—hematologic cancer	2.37e-05	9.43e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—PIK3R1—hematologic cancer	2.36e-05	9.39e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—CD80—hematologic cancer	2.36e-05	9.38e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—PIK3CG—hematologic cancer	2.35e-05	9.36e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—KIT—hematologic cancer	2.35e-05	9.36e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—NRAS—hematologic cancer	2.35e-05	9.36e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—CDKN1A—hematologic cancer	2.35e-05	9.33e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—PTPN11—hematologic cancer	2.34e-05	9.32e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—PTEN—hematologic cancer	2.34e-05	9.31e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—PTPN11—hematologic cancer	2.34e-05	9.29e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—CCND1—hematologic cancer	2.32e-05	9.24e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—JUN—hematologic cancer	2.32e-05	9.22e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—PTPN11—hematologic cancer	2.31e-05	9.2e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—MAPK8—hematologic cancer	2.29e-05	9.11e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling by GPCR—AKT1—hematologic cancer	2.28e-05	9.09e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—MAPK3—hematologic cancer	2.28e-05	9.08e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—MAPK3—hematologic cancer	2.28e-05	9.05e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—CREB1—hematologic cancer	2.27e-05	9.03e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—CREB1—hematologic cancer	2.26e-05	9e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—MAPK3—hematologic cancer	2.25e-05	8.97e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—CDKN1A—hematologic cancer	2.25e-05	8.94e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—PTEN—hematologic cancer	2.24e-05	8.92e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—BRAF—hematologic cancer	2.24e-05	8.92e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—CREB1—hematologic cancer	2.24e-05	8.91e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—BRAF—hematologic cancer	2.23e-05	8.89e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—EP300—hematologic cancer	2.23e-05	8.88e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—CCL2—hematologic cancer	2.22e-05	8.83e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—IL6R—hematologic cancer	2.21e-05	8.81e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—CCL2—hematologic cancer	2.21e-05	8.81e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—BRAF—hematologic cancer	2.21e-05	8.8e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—CREBBP—hematologic cancer	2.21e-05	8.79e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—IL6R—hematologic cancer	2.21e-05	8.78e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—CREBBP—hematologic cancer	2.2e-05	8.77e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—MAPK8—hematologic cancer	2.19e-05	8.73e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—CCL2—hematologic cancer	2.19e-05	8.72e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling by GPCR—AKT1—hematologic cancer	2.19e-05	8.7e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—IL6R—hematologic cancer	2.19e-05	8.69e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—CREBBP—hematologic cancer	2.18e-05	8.68e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—PIK3CB—hematologic cancer	2.18e-05	8.66e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—SRC—hematologic cancer	2.17e-05	8.64e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—EP300—hematologic cancer	2.14e-05	8.51e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—VEGFA—hematologic cancer	2.12e-05	8.41e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—MAP2K1—hematologic cancer	2.11e-05	8.39e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—MAP2K1—hematologic cancer	2.1e-05	8.37e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—PIK3CD—hematologic cancer	2.1e-05	8.34e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—STAT3—hematologic cancer	2.09e-05	8.33e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—PIK3CD—hematologic cancer	2.09e-05	8.31e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—NRAS—hematologic cancer	2.09e-05	8.31e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—MAP2K1—hematologic cancer	2.08e-05	8.29e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—SRC—hematologic cancer	2.08e-05	8.27e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—GPCR downstream signaling—PIK3CA—hematologic cancer	2.08e-05	8.26e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—GPCR downstream signaling—PIK3CA—hematologic cancer	2.07e-05	8.23e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—PIK3CD—hematologic cancer	2.07e-05	8.23e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—KRAS—hematologic cancer	2.05e-05	8.16e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—GPCR downstream signaling—PIK3CA—hematologic cancer	2.05e-05	8.15e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—KRAS—hematologic cancer	2.05e-05	8.14e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—KRAS—hematologic cancer	2.03e-05	8.06e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—VEGFA—hematologic cancer	2.03e-05	8.06e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—FGF2—hematologic cancer	2.01e-05	7.98e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—STAT3—hematologic cancer	2.01e-05	7.98e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—MAPK3—hematologic cancer	2e-05	7.96e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—FGF2—hematologic cancer	2e-05	7.96e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—NRAS—hematologic cancer	2e-05	7.96e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—FGF2—hematologic cancer	1.98e-05	7.88e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—PIK3R1—hematologic cancer	1.98e-05	7.87e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—PIK3R1—hematologic cancer	1.97e-05	7.85e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—PIK3R1—hematologic cancer	1.95e-05	7.77e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—MYC—hematologic cancer	1.95e-05	7.74e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—TGFB1—hematologic cancer	1.94e-05	7.72e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—JAK2—hematologic cancer	1.92e-05	7.65e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—JAK2—hematologic cancer	1.92e-05	7.63e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—MAPK3—hematologic cancer	1.92e-05	7.62e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—JAK2—hematologic cancer	1.9e-05	7.55e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—PIK3CA—hematologic cancer	1.89e-05	7.5e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—PTEN—hematologic cancer	1.88e-05	7.49e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—PIK3CA—hematologic cancer	1.88e-05	7.48e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—MDM2—hematologic cancer	1.88e-05	7.47e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—MDM2—hematologic cancer	1.87e-05	7.45e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—MYC—hematologic cancer	1.86e-05	7.41e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—PIK3CA—hematologic cancer	1.86e-05	7.4e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—TGFB1—hematologic cancer	1.86e-05	7.39e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—MDM2—hematologic cancer	1.85e-05	7.37e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—MTOR—hematologic cancer	1.83e-05	7.27e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—PIK3CB—hematologic cancer	1.83e-05	7.27e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—PIK3CB—hematologic cancer	1.82e-05	7.24e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—MTOR—hematologic cancer	1.82e-05	7.24e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—MTOR—hematologic cancer	1.8e-05	7.17e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—PIK3CB—hematologic cancer	1.8e-05	7.17e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—KRAS—hematologic cancer	1.8e-05	7.15e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—EP300—hematologic cancer	1.8e-05	7.14e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—HRAS—hematologic cancer	1.74e-05	6.94e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—HRAS—hematologic cancer	1.74e-05	6.92e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—HRAS—hematologic cancer	1.72e-05	6.85e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—KRAS—hematologic cancer	1.72e-05	6.85e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—CDKN1B—hematologic cancer	1.72e-05	6.82e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—CDKN1B—hematologic cancer	1.71e-05	6.8e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—GPCR downstream signaling—AKT1—hematologic cancer	1.7e-05	6.75e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—CDKN1B—hematologic cancer	1.69e-05	6.73e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—GPCR downstream signaling—AKT1—hematologic cancer	1.69e-05	6.73e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—CASP3—hematologic cancer	1.68e-05	6.68e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—IL2—hematologic cancer	1.68e-05	6.67e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—CASP3—hematologic cancer	1.68e-05	6.66e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—GPCR downstream signaling—AKT1—hematologic cancer	1.67e-05	6.66e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—IL2—hematologic cancer	1.67e-05	6.65e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—IL6—hematologic cancer	1.67e-05	6.64e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—IL6—hematologic cancer	1.66e-05	6.62e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—CASP3—hematologic cancer	1.66e-05	6.6e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—IL2—hematologic cancer	1.66e-05	6.59e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—PIK3CA—hematologic cancer	1.65e-05	6.57e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—IL6—hematologic cancer	1.65e-05	6.56e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—CCND1—hematologic cancer	1.64e-05	6.51e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—JUN—hematologic cancer	1.63e-05	6.49e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—CCND1—hematologic cancer	1.63e-05	6.49e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—JUN—hematologic cancer	1.63e-05	6.47e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—CCND1—hematologic cancer	1.62e-05	6.42e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—JUN—hematologic cancer	1.61e-05	6.41e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—TP53—hematologic cancer	1.6e-05	6.36e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—CDKN1A—hematologic cancer	1.58e-05	6.29e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—PIK3CA—hematologic cancer	1.58e-05	6.29e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—PTEN—hematologic cancer	1.58e-05	6.28e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—CDKN1A—hematologic cancer	1.58e-05	6.27e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—PTEN—hematologic cancer	1.57e-05	6.26e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—CDKN1A—hematologic cancer	1.56e-05	6.21e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—PTEN—hematologic cancer	1.56e-05	6.2e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—MAPK8—hematologic cancer	1.54e-05	6.14e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—AKT1—hematologic cancer	1.54e-05	6.13e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—MAPK8—hematologic cancer	1.54e-05	6.12e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—AKT1—hematologic cancer	1.54e-05	6.11e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—TP53—hematologic cancer	1.53e-05	6.09e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—HRAS—hematologic cancer	1.53e-05	6.08e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—MAPK8—hematologic cancer	1.52e-05	6.06e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—AKT1—hematologic cancer	1.52e-05	6.05e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—EP300—hematologic cancer	1.51e-05	5.99e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—EP300—hematologic cancer	1.5e-05	5.97e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—EP300—hematologic cancer	1.49e-05	5.91e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—SRC—hematologic cancer	1.46e-05	5.82e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—HRAS—hematologic cancer	1.46e-05	5.82e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—IL6—hematologic cancer	1.46e-05	5.82e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—SRC—hematologic cancer	1.46e-05	5.81e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—SRC—hematologic cancer	1.45e-05	5.75e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—VEGFA—hematologic cancer	1.43e-05	5.67e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—VEGFA—hematologic cancer	1.42e-05	5.65e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—STAT3—hematologic cancer	1.41e-05	5.62e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—NRAS—hematologic cancer	1.41e-05	5.6e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—VEGFA—hematologic cancer	1.41e-05	5.6e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—STAT3—hematologic cancer	1.41e-05	5.6e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—NRAS—hematologic cancer	1.4e-05	5.59e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—IL6—hematologic cancer	1.4e-05	5.57e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—STAT3—hematologic cancer	1.39e-05	5.54e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—NRAS—hematologic cancer	1.39e-05	5.53e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—AKT1—hematologic cancer	1.35e-05	5.37e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—MAPK3—hematologic cancer	1.35e-05	5.37e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—MAPK3—hematologic cancer	1.34e-05	5.35e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—MAPK3—hematologic cancer	1.33e-05	5.3e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—PIK3CA—hematologic cancer	1.33e-05	5.28e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—MYC—hematologic cancer	1.31e-05	5.22e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—TGFB1—hematologic cancer	1.31e-05	5.21e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—MYC—hematologic cancer	1.31e-05	5.2e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—TGFB1—hematologic cancer	1.3e-05	5.19e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—MYC—hematologic cancer	1.3e-05	5.15e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—AKT1—hematologic cancer	1.29e-05	5.14e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—TGFB1—hematologic cancer	1.29e-05	5.14e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—KRAS—hematologic cancer	1.21e-05	4.82e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—KRAS—hematologic cancer	1.21e-05	4.81e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—KRAS—hematologic cancer	1.2e-05	4.76e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—PIK3CA—hematologic cancer	1.11e-05	4.43e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—PIK3CA—hematologic cancer	1.11e-05	4.42e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—PIK3CA—hematologic cancer	1.1e-05	4.37e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—AKT1—hematologic cancer	1.08e-05	4.31e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—TP53—hematologic cancer	1.08e-05	4.29e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—TP53—hematologic cancer	1.07e-05	4.27e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—TP53—hematologic cancer	1.06e-05	4.23e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—HRAS—hematologic cancer	1.03e-05	4.1e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—HRAS—hematologic cancer	1.03e-05	4.09e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—HRAS—hematologic cancer	1.02e-05	4.05e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—IL6—hematologic cancer	9.86e-06	3.92e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—IL6—hematologic cancer	9.83e-06	3.91e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—IL6—hematologic cancer	9.74e-06	3.87e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—AKT1—hematologic cancer	9.1e-06	3.62e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—AKT1—hematologic cancer	9.07e-06	3.61e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—AKT1—hematologic cancer	8.98e-06	3.57e-05	CbGpPWpGaD
